Method of unidirectional solidification of castings and associated apparatus
    3.
    发明申请
    Method of unidirectional solidification of castings and associated apparatus 有权
    铸件和相关设备的单向凝固方法

    公开(公告)号:US20070012417A1

    公开(公告)日:2007-01-18

    申请号:US11484276

    申请日:2006-07-11

    摘要: Molten metal is injected uniformly into a horizontal mold from a feed chamber in a horizontal or vertical direction at a controlled rate, directly on top of the metal already within the mold. A cooling medium is applied to the bottom surface of the mold, with the type and flow rate of the cooling medium being varied to produce a controlled cooling rate throughout the casting process. The rate of introduction of molten metal and the flow rate of the cooling medium are both controlled to produce a relatively uniform solidification rate within the mold, thereby producing a uniform microstructure throughout the casting, and low stresses throughout the casting. A multiple layer ingot product is also provided comprising a base alloy layer and at least a first additional alloy layer, the two layers having different alloy compositions, where the first additional alloy layer is bonded directly to the base alloy layer by applying the first additional alloy in the molten state to the surface of the base alloy while the surface temperature of the base alloy is lower than the liquidus temperature and greater than eutectic temperature of the base alloy −50 degrees Celsuis.

    摘要翻译: 熔融金属以受控的速率从水平或垂直方向的进料室均匀地注入到水平模具中,直接在已经在模具内的金属的顶部上。 将冷却介质施加到模具的底表面,随着冷却介质的类型和流速的变化,以在整个铸造过程中产生受控的冷却速率。 控制熔融金属的引入速率和冷却介质的流量都被控制以在模具内产生相对均匀的凝固速率,从而在铸件中产生均匀的微观结构,并且在整个铸件中产生低应力。 还提供了多层锭产品,其包括基底合金层和至少第一附加合金层,所述两层具有不同的合金组成,其中第一附加合金层通过施加第一附加合金直接结合到基底合金层 在基体合金的表面温度低于液相线温度并且大于基体合金的共晶温度-50℃时,熔融状态下的熔融态。

    Chemokine mutants acting as chemokine antagonists
    4.
    发明授权
    Chemokine mutants acting as chemokine antagonists 失效
    趋化因子突变体作为趋化因子拮抗剂

    公开(公告)号:US07553483B2

    公开(公告)日:2009-06-30

    申请号:US10499100

    申请日:2002-12-16

    IPC分类号: A61K45/00 A61K39/00

    CPC分类号: C07K14/523 A61K38/00

    摘要: Mutants of specific CC-chemokines containing a non-conservative substitution in a conserved consensus sequence act as CC-chemokine antagonists, and can be effectively used in the treatment of autoimmune and inflammatory diseases, cancers, and viral or bacterial infections. Particularly preferred are the RANTES/CCL5 mutants having the amino acid sequence of SEQ ID NO: 1, 2, 3, or 4.

    摘要翻译: 在保守的共有序列中含有非保守取代的特异性CC-趋化因子的突变体作为CC-趋化因子拮抗剂,可以有效地用于治疗自身免疫性和炎性疾病,癌症和病毒或细菌感染。 特别优选的是具有SEQ ID NO:1,2,3或4的氨基酸序列的RANTES / CCL5突变体。

    Structured scintillator and systems employing structured scintillators
    5.
    发明授权
    Structured scintillator and systems employing structured scintillators 有权
    结构闪烁体和采用结构闪烁体的系统

    公开(公告)号:US07521685B2

    公开(公告)日:2009-04-21

    申请号:US11334718

    申请日:2006-01-18

    IPC分类号: G01T1/20 H01L27/148

    CPC分类号: G01T1/2018

    摘要: A structured scintillator and a detection system employing structured scintillators. More specifically, a structured scintillator comprising a scintillator material having a plurality of isolated structures is disclosed. The structures may be conical in shape. The structures may be formed on a substantially transparent material layer which has been patterned to form a plurality of isolated regions. The structures may be formed on top of the isolated regions to provide isolated scintillator structures having space therebetween. The isolated regions and scintillator structures may be aligned with underlying detection devices.

    摘要翻译: 结构化闪烁体和采用结构闪烁体的检测系统。 更具体地,公开了一种包括具有多个隔离结构的闪烁体材料的结构闪烁体。 结构可以是圆锥形的。 该结构可以形成在基本上透明的材料层上,该层被图案化以形成多个隔离区域。 可以在隔离区域的顶部上形成结构以提供在其间具有间隔的隔离的闪烁体结构。 隔离区域和闪烁体结构可以与底层检测装置对准。

    Position adjustable outlet box system
    7.
    发明授权
    Position adjustable outlet box system 有权
    位置可调式出气箱系统

    公开(公告)号:US06875922B1

    公开(公告)日:2005-04-05

    申请号:US10829754

    申请日:2004-04-22

    IPC分类号: H01H9/02 H02G3/12

    CPC分类号: H02G3/123 H01H9/0207

    摘要: A position adjustable outlet box system. The system has an outlet box cage, a mounting plate to which the outlet box cage is attached (having a outlet box aperture formed therein), an outlet box that is slideably retained in the outlet box cage, and a drywall ring having a projecting neck portion, which drywall ring is attachable to the outlet box. An adjustment mechanism is provided to permit adjustment of the depth position of the outlet box in the outlet box guide cage. The adjustment mechanism can includes a bolt that freely rotates along its axial axis (but does not move axially relative to the outlet box cage), a threaded shaft that screws into a threaded hole in a back wall of the outlet box and turning means that is accessible from within the outlet box to permit the outlet box's depth position within the cage to be adjusted as needed.

    摘要翻译: 一个位置可调式插座箱系统。 该系统具有出口箱保持架,安装板,出口箱保持架安装在该安装板上(其中形成有出口箱孔),可滑动地保持在出口箱笼中的出口箱,以及具有突出颈部的干墙环 部分,该干墙环可附接到出口箱。 提供调节机构以允许调节出口箱引导笼中的出口箱的深度位置。 调节机构可以包括沿其轴线自由旋转(但不相对于出口箱笼而不轴向移动)的螺栓,螺纹轴拧入出口箱的后壁中的螺纹孔和转动装置 可以从插座箱中进出,以便插座箱在笼内的深度位置可根据需要进行调整。

    Therapeutic uses of chemokine variants
    8.
    发明授权
    Therapeutic uses of chemokine variants 失效
    趋化因子变体的治疗用途

    公开(公告)号:US07740833B2

    公开(公告)日:2010-06-22

    申请号:US10573625

    申请日:2004-10-18

    摘要: Variants of homodimer-forming chemokines, such as human CCL2, having a single amino acid substitution in the dimerization interface that alters the pattern of hydrogen bonds and acting as an obligate monomer, can antagonize natural chemokines and have anti-inflammatory activity in vivo. These variants can be used as active ingredient in pharmaceutical compositions for the treatment of inflammatory, autoimmune, or infectious diseases.

    摘要翻译: 在二聚化界面中具有改变氢键图案和作为专性单体的单一氨基酸取代的同源二聚体形成趋化因子(例如人CCL2)的变体可以拮抗天然趋化因子并且在体内具有抗炎活性。 这些变体可用作用于治疗炎性,自身免疫性或感染性疾病的药物组合物中的活性成分。

    Novel CXCL8 antagonists
    9.
    发明申请
    Novel CXCL8 antagonists 审中-公开
    新型CXCL8拮抗剂

    公开(公告)号:US20090022657A1

    公开(公告)日:2009-01-22

    申请号:US10573726

    申请日:2004-10-22

    CPC分类号: C07K14/5421 A61K38/00

    摘要: Novel antagonists of the chemokine CXCL8 (also known as Interleukin-8) can be obtained by generating mutants having specific combinations of non-conservative substitutions of basic amino acids located in the C-terminal region. Compounds prepared in accordance with the present invention can be used to block CXCL8 activity in vivo, thereby providing therapeutic compositions for use in the treatment or prevention of CXCL8-related diseases.

    摘要翻译: 趋化因子CXCL8(也称为白细胞介素-8)的新型拮抗剂可以通过产生具有位于C-末端区域的碱性氨基酸的非保守取代的特异性组合的突变体来获得。 根据本发明制备的化合物可用于在体内阻断CXCL8活性,从而提供用于治疗或预防CXCL8相关疾病的治疗组合物。